Note: EPS may not be comparable

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of $0.25, versus ($0.35) reported last year. Revenue for the quarter came in at $87.32 million versus the consensus estimate of $48.56 million.

• Akebia reported net income for the fourth quarter of 2017 of $12.3 million, or $0.25 per diluted share, as compared to a net loss for the fourth quarter of 2016 of ($37.9) million, or ($0.99) per share. The net income reported for the fourth quarter of 2017 was attributable to $39.7 million of collaboration revenue recognized in connection with the MTPC agreement as the criteria for revenue recognition was satisfied in the fourth quarter.
• Collaboration revenue was $87.3 million for the fourth quarter of 2017 compared to $1.5 million for the fourth quarter of 2016, and $178.0 million for the full year of 2017 compared to $1.5 million for the full year of 2016.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.